



# **Shire Ireland Finance Trading Limited**

**Report and financial statements**

**For the financial year ended 31 March 2025**

# SHIRE IRELAND FINANCE TRADING LIMITED

## COMPANY INFORMATION

---

<b>Directors</b>	D A Ahern F Foley S O'Reilly
<b>Company secretary</b>	S O'Dowd
<b>Registered office</b>	Block 2, Miesian Plaza 50-58 Baggot Street Lower Dublin 2 Republic of Ireland
<b>Auditor</b>	KPMG Chartered Accountants 1 Stokes Place St. Stephen's Green Dublin 2 Republic of Ireland

# SHIRE IRELAND FINANCE TRADING LIMITED

## CONTENTS

---

	<b>Page</b>
Directors' Report	3
Statement of directors' responsibilities in respect of the directors' report and the financial statements	7
Independent auditor's report to the members of Shire Ireland Finance Trading Limited	8
Income Statement	11
Statement of financial position	12
Statement of changes in equity	13
Notes to the financial statements	14

# SHIRE IRELAND FINANCE TRADING LIMITED

## DIRECTORS' REPORT

### FOR THE YEAR ENDED 31 MARCH 2025

---

The Directors of Shire Ireland Finance Trading Limited ('the Company') present their directors' report and audited financial statements for the financial year ended 31 March 2025.

#### **Principal activities**

The Company was a wholly owned subsidiary within the Takeda Pharmaceutical Company Limited group during the year ('the Group' or 'Takeda'), a leading biopharmaceutical company bringing better health and a brighter future to people worldwide.

The Company's principal activity continued to be that of a financing company. During the year the Company managed its loans receivable and payable with fellow Group undertakings.

#### **Fair review of the business**

On 1 February 2025, the Company merged with Shire Pharmaceutical Services Ireland Limited, another entity within the Group. As part of this merger, all of Shire Pharmaceutical Services Ireland Limited's assets and liabilities were transferred to the Company and Shire Pharmaceutical Services Ireland Limited was dissolved by merger. The impact of this merger on the Company was not material.

The Company's presentation currency is US Dollars (\$).

The Company generated a profit before tax of \$0.9 billion in the financial year to 31 March 2025 (2024: \$1.2 billion).

The Company's net assets as at 31 March 2025 were \$9.9 billion (2024: \$11.6 billion). The decrease in net assets in the financial year was due mainly to dividends paid.

The Directors aim to maintain the management policies and continue to finance new opportunities. The assets and liabilities and financial position of the Company at the end of the financial year are set out on page 12.

#### **Principal risks and uncertainties**

The Company's operations are managed in conjunction with the objectives and performance of the Group. As a result, the principal risks and uncertainties of the Group influence and are therefore considered to be those of the Company.

In common with any biotechnology development and distribution business, the principal risks and uncertainties affecting the Company and Group are considered to relate to ongoing government regulation, control and approval, pricing and employee retention. Takeda group operations manage the risks discussed for all of its global companies and locations closely and has strong relationships in the markets.

Further information in respect of risk factors impacting the Company and the Group can be obtained from the Takeda Pharmaceutical Company Limited Annual Report, which does not form part of this annual report, and is available from the address in note 20.

# SHIRE IRELAND FINANCE TRADING LIMITED

## DIRECTORS' REPORT (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### **Financial risk management**

The Company's financial risks are managed on a Group basis.

#### **Financial risk factors**

The Group's activities expose it to a variety of financial risks: credit risk; liquidity risk and market risk (including foreign currency exchange risk, price risk and interest rate risk).

The Group's overall financial risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance. The Group uses derivative financial instruments to economically hedge certain risk exposures.

Financial risk management is carried out by a corporate treasury function conducted within a framework of policies and procedures approved periodically by Takeda committees. The corporate treasury function identifies, evaluates and hedges financial risks as needed for each subsidiary. As a matter of policy, the Group does not undertake speculative transactions that would increase currency or interest rate exposure.

Further information in respect of the financial risk management of the Group can be obtained from the Takeda Pharmaceutical Company Limited Annual Report, which does not form part of this annual report, and are available from the address in note 20.

#### **Key performance indicators**

The Company's operations are managed in conjunction with the objectives and performance of the Group. As a result, the key performance indicators of the Group influence and are therefore considered to be those of the Company.

Takeda has close involvement in the management of the Company and has used a range of key performance indicators. These are discussed in Takeda's Annual Report and financial statements, which do not form part of this annual report, and are available from the address in note 20.

#### **Directors**

The Directors who held office at any time during the financial year and up to the date of signature of the financial statements were as follows:

D A Ahern

F Foley

S O'Reilly

#### **Directors' and Secretary's Interest in Shares**

The directors and secretary held no interest in shares in the Company at 1 April 2024 and 31 March 2025. Their beneficial interests, including the interests of spouses and minor children, of the directors and the company secretary, in the share capital of the ultimate parent company were not in excess of 1% of the total issued share capital of the parent company at 1 April 2024 and 31 March 2025.

#### **Secretary**

The Secretary who held office at any time during the year and up to the date of signature of the financial statements was as follows:

S O'Dowd

#### **Results and dividends**

The results for the financial year are set out on page 11.

\$2,454 million ordinary dividends were paid (2024: \$5,258 million).

# SHIRE IRELAND FINANCE TRADING LIMITED

## DIRECTORS' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

---

### Going concern

The Directors observe the Company has net current assets at the balance sheet date. The Directors are able to observe the ability to meet the Company's obligations as they fall due.

The Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly the Directors continue to adopt the going concern basis of accounting in preparing the financial statements.

### Events after the reporting date

There have been no significant events after the reporting date that would require either adjustment to, or disclosure, in these financial statements.

### Auditor

KPMG continue in office in accordance with Section 383(2) of the Companies Act 2014.

### Accounting records

The measures that the Directors have taken to ensure compliance with Sections 281-285 inclusive of the Companies Act 2014 are the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The accounting records are held at Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Republic of Ireland.

### Political contributions

The company made no political donations nor incurred any political expenditure during the year (2024: \$nil).

### Statement on relevant audit information

So far as the Directors are aware, there is no relevant audit information of which the Company's statutory auditor is unaware. Additionally, the Directors have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the Company's statutory auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 330 of the Companies Act 2014.

### Audit committee

The Directors have considered Section 167 of the Companies Act 2014, which requires the board of directors of certain large entities to either establish an audit committee or decide not to establish such a committee. After giving this matter due consideration, the directors of the Company have resolved not to establish an audit committee.

In reaching that resolution, the directors have considered the financial reporting processes, the audits of its financial statements and the effectiveness of the Company's risk management and internal control framework in place already. In addition, the directors have taken into account the work carried out by the Audit & Supervisory Committee ("ASC") of Takeda Pharmaceutical Company Limited. The ASC review the consolidated quarterly and annual financial statements of the Group, the effectiveness of the system of internal control, internal audit and risk management (including that covering the financial reporting process), and recommends the appointment and removal of the external auditors. It monitors the adequacy of internal accounting practices and addresses all issues raised and recommendations made by the external auditors. The ASC pre-approves all audit and non-audit services provided to the Company by its external auditors and also reviews all services provided by the external auditor to review the independence and objectivity of the external auditor, taking into consideration relevant professional and regulatory requirements.

# SHIRE IRELAND FINANCE TRADING LIMITED

## DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025


---

### Compliance statement

It is the policy of the Company to comply with its relevant obligations (as defined in section 225 of the Companies Act 2014). The directors have drawn up a compliance policy statement as defined in section 225(3)(a) of the Companies Act 2014. Arrangements and structures have been put in place by the Group in respect of all of Takeda Pharmaceutical Company Limited's relevant subsidiaries (including the Company) that are, in the directors' opinion, designed to secure material compliance with the Company's relevant obligations. These arrangements and structures were under continuous review during the financial year and the directors consider these arrangements and structures to be appropriate.

As required by Section 225(2) of the Companies Act 2014, the Directors acknowledge that they are responsible for the Company's compliance with the relevant obligations. In discharging their responsibilities under Section 225, the Directors relied on the advice both of persons employed by the Group and of persons retained by the Group under contract, who they understand have the requisite knowledge and experience to advise the Company on compliance with its relevant obligations.

On behalf of the Board

Signed by:  
  
UDF2B6116313429...

F Foley  
Director

Date: 22 October 2025

DocuSigned by:  
  
1E0A5F111F93478...

D A Ahern  
Director

# SHIRE IRELAND FINANCE TRADING LIMITED

## STATEMENT OF DIRECTORS' RESPONSIBILITIES IN RESPECT OF THE DIRECTORS' REPORT AND THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 MARCH 2025

---

The directors are responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.


Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company and of its profit or loss for that year.


In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the Company and enable them to ensure that the financial statements are prepared in accordance with the applicable accounting framework and comply with the provisions of the Companies Act 2014. They are responsible for such internal controls as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities. The directors are also responsible for preparing a directors' report that complies with the requirements of the Companies Act 2014.

On behalf of the Board

Signed by:  
  
\_\_\_\_\_  
0DF2B6118313429...  
F Foley  
Director  
Date: 22 October 2025

DocuSigned by:  
  
\_\_\_\_\_  
1E0A5E111E93478  
D A Ahern  
Director



KPMG

Audit  
1 Stokes Place  
St. Stephen's Green  
Dublin 2  
D02 DE03  
Ireland

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHIRE IRELAND FINANCE TRADING LIMITED

---

### Report on the audit of the financial statements

#### Opinion

We have audited the financial statements of Shire Ireland Finance Trading Limited ('the Company') for the year ended 31 March 2025 set out on pages 11 to 27, which comprise the income statement, the statement of financial position, the statement of changes in equity and related notes, including the summary of significant accounting policies set out in note 1.

The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* issued in the United Kingdom by the Financial Reporting Council.

In our opinion:

- the financial statements give a true and fair view of the assets, liabilities and financial position of the Company as at 31 March 2025 and of its profit for the year then ended;
- the financial statements have been properly prepared in accordance with FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland*; and
- the financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

# INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHIRE IRELAND FINANCE TRADING LIMITED (CONTINUED)

---

## ***Other information***

The directors are responsible for the other information presented in the Annual Report together with the financial statements. The other information comprises the information included in the directors' report. The financial statements and our auditor's report thereon do not comprise part of the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work we have not identified material misstatements in the other information.

Based solely on our work on the other information undertaken during the course of the audit, we report that:

- we have not identified material misstatements in the directors' report;
- in our opinion, the information given in the directors' report is consistent with the financial statements; and
- in our opinion, those parts of the directors' report specified for our review, which does not include sustainability reporting when required by Part 28 of the Companies Act 2014, have been prepared in accordance with the Companies Act 2014.

## ***Our opinions on other matters prescribed by the Companies Act 2014 are unmodified***

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

## ***Matters on which we are required to report by exception***

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by Sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

## ***Respective responsibilities and restrictions on use***

### ***Responsibilities of directors for the financial statements***

As explained more fully in the directors' responsibilities statement set out on page 7, the directors are responsible for: the preparation of the financial statements including being satisfied that they give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

# INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHIRE IRELAND FINANCE TRADING LIMITED (CONTINUED)

---


## ***Auditor's responsibilities for the audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A fuller description of our responsibilities is provided on IAASA's website at <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements/>.

## ***The purpose of our audit work and to whom we owe our responsibilities***

Our report is made solely to the Company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



22 October 2025

Richard Hobson

**for and on behalf of**  
**KPMG**  
**Chartered Accountants, Statutory Audit Firm**  
1 Stokes Place  
St. Stephen's Green  
Dublin 2  
D02 DE03

**SHIRE IRELAND FINANCE TRADING LIMITED****INCOME STATEMENT****FOR THE YEAR ENDED 31 MARCH 2025**

	Note	Year to 31 Mar 2025 \$'000	Year to 31 Mar 2024 \$'000
Interest income and similar income	3	1,162,094	1,640,819
Interest expense and similar charges	4	(349,519)	(440,644)
<b>Net interest</b>		<u>812,575</u>	<u>1,200,175</u>
Other income		68,154	—
Administrative expenses		(11,027)	(20,320)
Profit on disposal of assets		—	6,237
Profit from dissolved operations	9	278	—
<b>Profit on ordinary activities before taxation</b>	5	<u>869,980</u>	<u>1,186,092</u>
Tax on profit on ordinary activities	7	(108,568)	(147,081)
<b>Profit on ordinary activities after taxation and profit for the financial year</b>		<u><u>761,412</u></u>	<u><u>1,039,011</u></u>

All of the results in the current and prior period were derived from continuing operations.


No other gains and losses other than those above have occurred, therefore no separate statement of comprehensive income has been prepared.

**SHIRE IRELAND FINANCE TRADING LIMITED****STATEMENT OF FINANCIAL POSITION****AS AT YEAR ENDED 31 MARCH 2025**

	Note	2025 \$'000	2024* \$'000
<b>Non-current assets</b>			
Financial assets	9	—	—
Debtors: amounts falling due after more than one year	12	11,372,648	13,640,074
		<u>11,372,648</u>	<u>13,640,074</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	10	3,772,176	5,396,507
Investments	11	352,257	272,415
		<u>4,124,433</u>	<u>5,668,922</u>
<b>Current Liabilities</b>			
Creditors: amounts falling due within one year	13	(2,522,732)	(1,786,417)
		<u>1,601,701</u>	<u>3,882,505</u>
<b>Net current assets</b>			
		<u>1,601,701</u>	<u>3,882,505</u>
<b>Total assets less current liabilities</b>			
		<u>12,974,349</u>	<u>17,522,579</u>
<b>Non current liabilities</b>			
Creditors: Amounts falling due after more than one year	14	(3,096,571)	(5,952,447)
		<u>9,877,778</u>	<u>11,570,132</u>
<b>Net assets</b>			
		<u>9,877,778</u>	<u>11,570,132</u>
<b>Capital and reserves</b>			
Called up share capital presented as equity	17	3,613,215	3,613,215
Share premium account	17	1,785,487	1,785,487
Other reserves - capital redemption reserve	17	497,779	497,779
Profit and loss account	17	3,981,297	5,673,651
<b>Total equity</b>		<u>9,877,778</u>	<u>11,570,132</u>

\*Prior year comparatives within current assets have been represented to better reflect the operations of the entity.

The financial statements on pages 11 to 27 were approved by the Board of Directors, authorised for issue and are signed on its behalf by:

Signed by:  
  
 ODF2B6118313429...

F Foley

Director

Date: 22 October 2025

DocuSigned by:  
  
 1E0A5F111F93478...

D A Ahern

Director

**SHIRE IRELAND FINANCE TRADING LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 31 MARCH 2025**

	Called up share capital \$'000	Share premium account \$'000	Capital redemption reserve \$'000	Profit and loss account \$'000	Total \$'000
<b>1 April 2023</b>	3,613,215	1,785,487	497,779	9,894,417	15,790,898
Profit and total comprehensive income for the period	—	—	—	1,039,011	1,039,011
Transactions with owners in their capacity as owners:					
Distribution to shareholder (see note 8)	—	—	—	(5,257,548)	(5,257,548)
Other movements in Profit and loss account	—	—	—	(2,229)	(2,229)
<b>31 March 2024</b>	3,613,215	1,785,487	497,779	5,673,651	11,570,132
Profit and total comprehensive income for the year	—	—	—	761,412	761,412
Transactions with owners in their capacity as owners:					
Distribution to shareholder (see note 8)	—	—	—	(2,453,766)	(2,453,766)
<b>31 March 2025</b>	3,613,215	1,785,487	497,779	3,981,297	9,877,778

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### 1. Accounting policies

##### General information

Shire Ireland Finance Trading Limited (“the Company”) is a private company limited by shares incorporated and domiciled in the Republic of Ireland, under the Companies Act 2014.

The address of the Company’s registered office and principal place of business is Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Republic of Ireland.

The Company’s principal activities and the nature of its operations are discussed in the Directors’ Report on pages 3 to 6.

##### Basis of accounting

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of Irish statute comprising the Companies Act 2014, and under the historical cost convention. There have been no material departures from the standard. The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements. Judgements made by the directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in note 2.\$

##### Reduced disclosures

In accordance with FRS 102, the Company has taken advantage of the exemptions from the following disclosure requirements:

- Section 4 ‘Statement of Financial Position’ – Reconciliation of the opening and closing number of shares.
- Section 7 ‘Statement of Cash Flows’ – Presentation of a Statement of Cash Flow and related notes and disclosures.
- Section 11 ‘Basic Financial Instruments’ & Section 12 ‘Other Financial Instrument Issues’ – Carrying amounts, interest income/expense and net gains/losses for each category of financial instrument; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income.
- Section 26 ‘Share-based Payment’ – Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements.
- Section 33 ‘Related Party Disclosures’ – Compensation for key management personnel.

The financial statements of the Company are consolidated in the financial statements of Takeda Pharmaceutical Company Limited. The consolidated financial statements of Takeda Pharmaceutical Company Limited are available from the address in note 20

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### 1. Accounting policies (continued)

##### Going concern

The Directors observe the Company has net current assets at the balance sheet date and therefore the ability to meet the Company's obligations as they fall due.

The Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly the Directors continue to adopt the going concern basis of accounting in preparing the financial statements.

##### Functional and presentational currencies

The financial statements are presented in US Dollars (\$) which is also the functional currency of the Company.

Monetary amounts in these financial statements are rounded to the nearest whole \$1,000, except where otherwise indicated.

##### Foreign currencies

Transactions in currencies other than the functional currency (foreign currencies) are initially recorded at the exchange rate prevailing on the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies are translated at the rate ruling at the date of the transaction or, if the asset or liability is measured at fair value, the rate when that fair value was determined.

All translation differences are taken to profit or loss, except to the extent that they relate to gains or losses on non-monetary items recognised in other comprehensive income, when the related translation gain or loss is also recognised in other comprehensive income.

##### Borrowing costs

Borrowing costs are expensed as incurred.

##### Taxation

The tax expense represents the sum of the current tax expense and deferred tax expense. Current tax assets are recognised when tax paid exceeds the tax payable.

Current tax is based on taxable profit for the year. Taxable profit differs from total comprehensive income because it excludes items of income or expense that are taxable or deductible in other periods. Current tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted by the reporting date.

Deferred tax is calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled based on tax rates that have been enacted or substantively enacted by the reporting date. Deferred tax is not discounted.

Deferred tax liabilities are recognised in respect of all timing differences that exist at the reporting date. Timing differences are differences between taxable profits and total comprehensive income that arise from the inclusion of income and expenses in tax assessments in different periods from their recognition in the financial statements. Deferred tax assets are recognised only to the extent that it is probable that they will be recovered by the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination and the amounts that can be deducted or assessed for tax. The deferred tax recognised is adjusted against goodwill.

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### 1. Accounting policies (continued)

Current and deferred tax is charged or credited in profit or loss, except when it relates to items charged or credited to other comprehensive income or equity, when the tax follows the transaction or event it relates to and is also charged or credited to other comprehensive income, or equity.

Current tax assets and current tax liabilities and deferred tax assets and deferred tax liabilities are offset, if and only if, there is a legally enforceable right to set off the amounts and the entity intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

#### **Employee benefits**

The costs of short-term employee benefits are recognised as a liability and an expense.

#### **Retirement benefits**

##### *Defined contribution pension plan*

The Company contributes to personal defined contribution pension plans of employees. Contributions are charged to the profit and loss account as they become payable. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in the balance sheet.

#### **Cash at bank and in hand**

Cash at bank and in hand includes cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts.

#### **Financial instruments**

The Company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102, in full, to all of its financial instruments.

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument, and are offset only when the Company currently has a legally enforceable right to set off the recognised amounts and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

#### **Financial assets**

##### *Basic financial assets*

Basic financial assets, which include trade and other receivables, amounts owed by Group undertakings, and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Money market funds and liquid investments refer to investments in short-term, high-quality, highly liquid debt instruments and cash equivalents. Examples of such instruments include treasury bills, commercial paper, certificates of deposit, and repurchase agreements. The primary objectives of money market funds are preservation of capital, liquidity, and generation of a modest return. Investments in money market funds are classified as cash equivalents in the statement of financial position if they have original maturities of three months or less from the date of acquisition. Money market funds that do not qualify as cash equivalents are classified as short-term investments under current assets. Money market funds are measured at fair value. Upon acquisition, investments in money market funds are initially recognized at fair value, which typically reflects the transaction price (the amount paid to acquire the investment, including directly attributable transaction costs if material). Subsequent to initial recognition, money market fund investments are measured at fair value at each reporting date. The fair value is determined using quoted market prices or unobservable inputs when quoted prices are not available. Changes in fair value are recognized in profit or loss. The company utilizes money market funds as part of its liquidity management strategy, to ensure sufficient access to

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

cash for operational needs while optimizing interest income. The company monitors interest rate risk, credit risk, and liquidity risk associated with exposure to these funds (See Note 11).

#### *Impairment*

A provision for impairment of financial assets is established when there is objective evidence that the amounts due will not be collected according to the original terms of the contract. Impairment losses are recognised in profit or loss for the excess of the carrying value of the asset over the present value of the future cash flows discounted using the original effective interest rate. Subsequent reversals of an impairment loss that objectively relate to an event occurring after the impairment loss was recognised, are recognised immediately in profit or loss.

#### **Financial liabilities and equity**

Financial instruments are classified as liabilities and equity instruments according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

#### *Equity instruments*

Financial instruments classified as equity instruments are recorded at the fair value of the cash or other resources received or receivable, net of direct costs of issuing the equity instruments.

#### *Basic financial liabilities*

Basic financial liabilities, including trade and other payables, and amounts owed to Group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors payable within one year that do not constitute a financing transaction are initially measured at the transaction price and subsequently measured at amortised cost, being the transaction price less any amounts settled.

Where the arrangement with a trade creditor constitutes a financing transaction, the creditor is initially and subsequently measured at the present value of future payments discounted at a market rate of interest for a similar instrument.

#### *De-recognition of financial assets and liabilities*

A financial asset is derecognised only when the contractual rights to cash flows expire or are settled, or substantially all the risks and rewards of ownership are transferred to another party, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party. A financial liability (or part thereof) is derecognised when the obligation specified in the contract is discharged, cancelled or expires.

#### *Derivatives*

Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured to fair value, at each reporting date. Fair value gains and losses are recognised in profit or loss unless hedge accounting is applied and the hedge is a cash flow hedge.

#### *Fair value accounting*

Certain financial instruments have been recorded at fair value, where this differs from the historic cost measurement or expected cash-flows of the financial instrument. Such fair value calculations are performed in conjunction with qualified experts engaged by the Company. The fair value adjustment is recorded on the balance sheet and amortised over the terms of the underlying financial instrument.

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

### Share based payments

The Company participates in cash-settled share-based payments, which are granted based on the service performed by the employees, directors, and senior management. The service received and the corresponding liability are measured at the fair value of the corresponding liability. The fair value of the liability-classified awards granted to employees, directors, and senior management are recognized as expense over the vesting period of the awards with a corresponding amount as an increase in liability. The Company re-measures the fair value of the liability at the end of each reporting period and at the date of settlement, and recognizes any changes in fair value in profit or loss.

### Dividends

Dividends are recognised as liabilities once they are no longer at the discretion of the Company.

### Provisions

Provisions are recognised when the Company has an obligation at the reporting date as a result of a past event which it is probable will result in the transfer of economic benefits and that obligation can be estimated reliably.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

## 2. Critical accounting estimates and areas of judgement

In the application of the Company's accounting policies, which are described in note 1, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

### *Critical accounting estimates and areas of judgement*

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

In assessing the recoverability of the Company's debtors, management makes assumptions as to the probability of the debt becoming bad by considering the age of the debt, the payment terms of the contract, the credibility of the counterparty and historic knowledge.

## 3. Interest income and similar income

	Year to 31 Mar 2025	Year to 31 Mar 2024
	\$'000	\$'000
Interest receivable on loans due from Group undertakings	1,142,627	1,628,523
Interest receivable on bank term deposits and money market and liquidity funds	19,467	12,296
	<u>1,162,094</u>	<u>1,640,819</u>

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****4. Interest expense and similar charges**

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Interest payable on loans due to Group undertakings	349,519	440,578
Bank charges	—	66
	<u>349,519</u>	<u>440,644</u>

**5. Profit on ordinary activities before taxation**

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit before taxation is stated after charging/(crediting):	<b>\$'000</b>	<b>\$'000</b>
(Profit)/loss from dissolved operations	(278)	—
(Profit)/loss on disposal of assets	—	(6,237)
Share based payments expense	186	416
(Gains)/losses from foreign exchange derivatives contracts	(10,683)	2,642
Other foreign exchange gains	(7,296)	(561)

Fees payable to the statutory auditor in respect of audit services are as follows:

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Audit services – statutory audit of the Company	<u>34</u>	<u>30</u>

All fees payable noted above were borne by another Group company, and no recharge was made to the Company in respect of these costs in the current and prior year.

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****6. Employees**

The average monthly number of persons (including Directors) employed by the Company during the financial year was:

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
The average monthly number of persons (including directors) employed by the Company during the year was:	<b>No</b>	<b>No</b>
Directors	1	1
Administration staff	6	7
	<u>7</u>	<u>8</u>

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
Staff costs for the above persons:	<b>\$'000</b>	<b>\$'000</b>
Wages and salaries	1,494	1,309
Social insurance costs	160	169
Company contributions to money purchase pension schemes	105	111
Employee share schemes	186	416
	<u>1,945</u>	<u>2,005</u>

	<b>Year to 31 Mar 2025</b>	<b>Year to 31 Mar 2024</b>
In respect of the Directors of Shire Ireland Finance Trading Limited:	<b>\$'000</b>	<b>\$'000</b>
Emoluments in respect of qualifying services	269	257
Company contributions to defined contribution pension schemes	25	24
Employee share schemes (note 18)	64	116
	<u>358</u>	<u>397</u>

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****7. Tax on profit on ordinary activities**

	Year to 31 Mar 2025 \$'000	Year to 31 Mar 2024 \$'000
<b>Current tax</b>		
Irish corporation tax	108,681	147,548
Foreign corporation tax charge for the year	2,775	1,146
Double taxation relief on overseas taxes	(2,369)	(1,014)
Adjustments in respect of previous years	(638)	(549)
Total current tax	<u>108,449</u>	<u>147,131</u>
<b>Deferred tax</b>		
Origination and reversal of timing differences	21	(50)
Adjustments in respect of previous years	98	—
Total deferred tax	<u>119</u>	<u>(50)</u>
Total tax on profit on ordinary activities	<u><u>108,568</u></u>	<u><u>147,081</u></u>

Factors affecting the tax charge for the financial year.

The tax assessed for the period is lower (2024: lower) than the standard rate of corporation tax in Ireland of 12.5%. The differences are explained below:

	Year to 31 Mar 2025 \$'000	Year to 31 Mar 2024 \$'000
Company profit on ordinary activities before tax	<u>869,980</u>	<u>1,186,092</u>
Company profit on ordinary activities multiplied by the standard rate of corporation tax of 12.5% (2024: 12.5%)	108,748	148,262
Effects of:		
Income not taxable	(1)	(769)
Income tax at higher rate	406	132
Trade related income foreign tax deducted	(51)	—
Adjustments in respect of previous years	(540)	(549)
Income tax charged to tax liability	5	3
Other	1	2
	<u><u>108,568</u></u>	<u><u>147,081</u></u>

The standard rate of tax applied to reported profit on ordinary activities is 12.5 per cent. Corporation tax is charged at a rate of 12.5% on trading income. Corporation tax is charged at 25% on passive income.

Details of recognised deferred tax assets are set out in note 16.

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****8. Dividends**

	Year to 31 Mar 2025 \$'000	Year to 31 Mar 2024 \$'000
Interim Ordinary dividends paid of \$8.47 (Year to 31 Mar 2024: \$18.15) per ordinary share	2,453,766	5,257,548
	<u>2,453,766</u>	<u>5,257,548</u>

**9. Financial assets**

	Shire Pharmaceutical Services Ireland Limited	Shares in Group undertakings
	\$'000	\$'000
<b>Financial assets</b>		
<b>Cost</b>		
As at 1 April 2024	—	—
Additions	835	835
Disposals	(835)	(835)
As at 31 March 2025	<u>—</u>	<u>—</u>
<b>Impairment</b>		
As at 1 April 2024	—	—
Charge in year	—	—
As at 31 March 2025	<u>—</u>	<u>—</u>
<b>Net book value</b>		
As at 31 March 2025	<u>—</u>	<u>—</u>
As at 31 March 2024	<u>—</u>	<u>—</u>

On 1 February 2025, the Company merged with Shire Pharmaceutical Services Ireland Limited, another entity within the Group. As part of this merger, all of Shire Pharmaceutical Services Ireland Limited's assets and liabilities were transferred to the Company and Shire Pharmaceutical Services Ireland Limited was dissolved by merger.

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****10. Debtors: amounts falling due within one year**

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Amounts owed from Group undertakings	3,772,176	5,396,502
Other debtors	—	5
	<u>3,772,176</u>	<u>5,396,507</u>

Included within amounts due from Group undertakings are amounts of \$3,553 million (2024: \$4,701 million) that are denominated in US Dollars and \$0 (2024: \$406 million) that are denominated in Euros. Amounts of \$1,053 million (2024: \$947 million) bear interest at a variable rate and \$2,500 million (2024: \$4,160 million) bear interest at fixed rates. At 31 March 2025 interest of \$214 million (2024: \$286 million) is accrued but unpaid on these amounts. Also included within amounts due from Group undertakings are amounts of \$4 million (2024: \$3 million) that are derivative financial instruments. The remaining balance in amount of \$2 million (2024: \$0) relates to trade receivables and other debtors with Group entities. These are issued under the Company's usual credit terms.

**11. Current asset investments and other financial assets**

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Money market and liquidity funds	352,257	272,415
	<u>352,257</u>	<u>272,415</u>

**12. Debtors: amounts falling due after more than one year**

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Amounts owed by Group undertakings	11,372,614	13,639,921
Deferred tax assets (see note 16)	34	153
	<u>11,372,648</u>	<u>13,640,074</u>

Included within amounts due from Group undertakings are amounts of \$11,144 million (2024: \$13,640 million) that are denominated in US Dollars, and \$227 million (2024: \$0) that are denominated in Euros. Amounts of \$227 million (2024: \$0) bear interest at a variable rate and \$11,144 million (2024: \$13,640 million) bear interest at fixed rates. The remaining balance in amount of \$1 million (2024: \$0) relates to other intercompany investment.

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025****13. Creditors: amounts falling due within one year**

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Trade creditors	49	102
Amounts owed to Group undertakings	2,521,535	1,781,065
Accruals	510	1,059
Other taxation and social insurance	5	—
Corporation tax	633	4,191
	<u>2,522,732</u>	<u>1,786,417</u>

Included within amounts owed to Group undertakings are amounts of \$2,178 million (2024: \$118 million) that are denominated in US Dollars and \$0 (2024: \$434 million) that are denominated in Euros. Amounts of \$2,178 million (2024: \$552 million) bear interest at a variable rate and amounts of \$0 (2024: \$0) bear interest at fixed rates. At 31 March 2025 interest of \$12 million (2024: \$19 million) is accrued but unpaid on these amounts. The remaining balance primarily relates to the in-house bank current balance in amount of \$332 million (2024: \$1,210 million).

**14. Creditors: amounts falling due after more than one year**

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Amounts owed to Group undertakings	3,096,471	5,952,275
Other creditors	100	172
	<u>3,096,571</u>	<u>5,952,447</u>

Included within amounts owed to Group undertakings are amounts of \$2,756 million (2024: \$5,952 million) that are denominated in US Dollars and \$341 million (2024: \$0) that are denominated in Euros. Amounts of \$1,596 million (2024: \$2,952 million) bear interest at a variable rate and amounts of \$1,500 million (2024: \$3,000 million) bear interest at fixed rates.

**15. Financial instruments**

The carrying values of the company's financial assets and liabilities measured at fair value through profit or loss are summarised by category below:

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>Financial assets at fair value</b>		
<i>Measured at fair value through profit or loss</i>		
Derivative financial assets (see note 10)	3,554	3,320
Money market and liquidity funds (see note 11)	352,257	272,415
<b>Financial liabilities at fair value</b>		
<i>Measured at fair value through profit or loss</i>		
Derivative financial liabilities (see note 13)	—	—
	—	—

**SHIRE IRELAND FINANCE TRADING LIMITED****NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)****FOR THE YEAR ENDED 31 MARCH 2025**

The company's income, expense, gains and losses in respect of the above financial instruments are summarised below:

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
<b>Fair value gains</b>		
On financial assets measured at fair value through profit or loss	58,136	18,614
On financial liabilities measured at fair value through profit or loss	(47,453)	(21,256)
	<u>10,683</u>	<u>(2,642)</u>

The Company does not have credit risk related contingent features or collateral linked to the derivatives.

Management believes that the carrying values approximate their fair values for the above derivatives.

**16. Deferred taxation**

	<b>2025</b>
	<b>\$'000</b>
As at 1 April 2024 (asset)	(153)
Debit in relation to the prior year	98
Debit in the year	21
As at 31 March 2025 (asset)	<u>(34)</u>

The major deferred tax assets recognised by the Company are:

	<b>2025</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
Timing differences	(34)	(153)
	<u>(34)</u>	<u>(153)</u>

The above recognised deferred tax assets were regarded as recoverable and therefore recognised only when, on the basis of all available evidence, it was regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

**17. Called up share capital presented as equity****Called up share capital**

	<b>2025</b>	<b>2025</b>	<b>2024</b>	<b>2024</b>
	<b>No</b>	<b>\$'000</b>	<b>No</b>	<b>\$'000</b>
<b><u>Allotted called up, issued and fully paid</u></b>				
Ordinary shares of \$0.77 each	289,673,364	223,048	289,673,364	223,048
Redeemable ordinary shares of \$0.77 each	4,402,814,035	3,390,167	4,402,814,035	3,390,167
<b>Total</b>	<b><u>4,692,487,399</u></b>	<b><u>3,613,215</u></b>	<b><u>4,692,487,399</u></b>	<b><u>3,613,215</u></b>

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

All called-up share capital above is presented as equity.

#### *Ordinary share rights*

Ordinary shares have full rights in the company with respect to voting, dividends and distributions.

#### *Redeemable share rights*

Redeemable shares have full rights in the company with respect to voting, dividends and distributions. They are redeemable at the discretion of the company.

### **Reserves**

#### *Share premium*

Consideration received for shares issued above their nominal value net of transaction costs.

#### *Capital redemption reserve*

The Capital Redemption Reserve is a statutory reserve created when the company redeemed shares previously held by Shire Ireland Investment Limited as a result of group restructuring in 2020. The amount transferred to this reserve was equal to the nominal value of the shares redeemed.

#### *Profit and loss account*

Cumulative profit and loss net of distributions to owners.

## **18. Share based payments**

#### *Group share based payment arrangements*

The Company participated in group share-based payment arrangements and recognises and measures its share-based payment expense on the basis of a reasonable allocation of the expense recognised for the Group.

The required disclosures are therefore included in the Takeda Pharmaceutical Company Limited consolidated financial statements.

The Company participates in cash-settled share-based payments, which are granted based on the service performed by the employees, directors, and senior management. The service received and the corresponding liability are measured at the fair value of the corresponding liability. The fair value of the liability-classified awards granted to employees, directors, and senior management are recognized as expense over the vesting period of the awards with a corresponding amount as an increase in liability. Takeda re-measures the fair value of the liability at the end of each reporting period and at the date of settlement, and recognizes any changes in fair value in profit or loss.

Takeda has a restricted stock units (RSUs) plan for certain of its employees. The value of these awards is linked to share price of Takeda Pharmaceutical Company Limited and are settled in cash.

The total compensation expense recorded associated with these plans is disclosed in note 6.

The total liability reflected in the statement of financial position is included within accruals disclosed in note 13.

#### *Restricted stock units (RSUs)*

The RSUs vest one third each year over a three-year period from the end of the fiscal year during which the awards were granted. The RSUs are settled upon vesting based on the share price at the vesting date plus any dividends paid on shares during the vesting period. There is no exercise price payable by the holder.

There are no exercisable balances at the current or prior year end.

# SHIRE IRELAND FINANCE TRADING LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2025

---

#### **19. Related party transactions**

The Company has taken advantage of the exemption in Section 33 of FRS 102 not to disclose transactions with wholly owned Group companies.

#### **20. Ultimate parent company**

The ultimate parent undertaking of the Company is Takeda Pharmaceutical Company Limited, a company incorporated in Japan. The head office of Takeda Pharmaceutical Company Limited address is 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan.

Takeda Pharmaceutical Company Limited, a company incorporated in Japan, is the immediate parent company of the Company. The registered office of Takeda Pharmaceutical Company Limited address is 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan.

At 31 March 2025, Takeda Pharmaceutical Company Limited heads the smallest and largest group which prepares consolidated accounts in which the results of the Company are included. The financial statements of Takeda Pharmaceutical Company Limited are available from the Company Secretary at the following address: 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan, which is also the registered office of the ultimate parent, and on the group website [www.takeda.com](http://www.takeda.com).

#### **21. Events after the reporting date**

There were no significant events after the reporting date that would require either adjustment to, or disclosure, in these financial statements.

**22.** The board of directors approved these financial statements for issue on 22 October 2025.